The Epstein-Barr virus nuclear antigen-leader protein (EBNA-LP) is required for high efficiency B lymphocyte growth transformation by the virus. To test the potential contribution of EBNA-LP to tumorigenesis in vivo, we produced transgenic mice carrying an EBNA-LP eDNA construct, using the widely expressed metallothionein promoter. Expression of EBNA-LP was detected in liver, kidney, heart, lung and spleen. There were no apparent oncogenic consequences of EBNA-LP expression. Unexpectedly however, at ages ranging from about 4 months to over a year, transgenic mice developed symptoms of congestive heart failure, including left ventricular dilatation, right ventricular hypertrophy, left atrial thrombosis, pulmonary oedema and hydrothorax. Fibrillation was not apparent in the electrocardiograph; however a reduction in T-wave amplitude suggested that the development of an abnormality of ventricular repolarization may precede the manifestation of overt symptoms. The highly predictable development of dilated heart failure in these transgenic mice suggests they may be a useful model for the pathophysiological changes associated with human dilated cardiomyopathy.
Introduction
The Epstein-Barr virus (EBV) is a common human herpesvirus with a complex life cycle involving chronic replication in epithelial tissues and virus persistence as a non-productive or 'latent' infection in B lymphocytes (Fields & Knipe, 1990) . Infection usually occurs asymptomatically in early childhood, whereas primary infection during adolescence can cause infectious mononucleosis (glandular fever). The subsequent lifelong persistence of the virus is generally asymptomatic, and kept in check by a cytotoxic T cell response (Rickinson et al., 1992) . However EBV is also associated with several major human malignancies including Burkitt's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.
Immortalized lymphoblastoid cell lines (LCLs) can be derived from B lymphocytes infected with EBV, and these express a limited set of nine viral proteins comprising the six EBV nuclear antigens [EBNA-1, EBNA-2, EBNA-3A/B/C, EBNA-leader protein (EBNA-LP)], three latent membrane proteins (LMP-1, LMP-2a and LMP-2b) as well as two small nuclear RNAs (EBERs). Although the minimal subset of viral proteins needed for immortalization has yet to be determined, both EBNA-2 and LMP-1 have major roles in growth transformation. The EBNA-2 protein is a trans-activator that upregulates transcription from EBV and cellular promoters (Abbot et al., 1990; Fahraeus et al., 1990; Wang et al., 1990) . Expression of EBNA-2 in rodent fibroblasts reduces their serum requirement for growth (Dambaugh et al., 1986) , and mutant viruses lacking the EBNA-2 gene are unable to transform B lymphocytes (Cohen et al., 1989; Hammerschmidt & Sugden, 1989; Skate et al., 1985) . Expression of the LMP-1 protein induces expression of cell surface markers associated with B lymphocyte activation in Burkitt's lymphoma lines and reduces their sensitivity to apoptosis through the upregulation of the bcl-2 proto-oncogene (Henderson et aL, 1991; Wang et al., 1988) . LMP-I expression also confers anchorage independence and tumorigenicity in some rodent fibroblast lines (Wang et al., 1985) and inhibits differentiation in human epithelial cell lines (Dawson et al., 1990; Fahraeus et al., 1990) . Consistent with the latter role, expression of LMP-1 in the skin of transgenic mice produced a phenotype of hyperplastic dermatosis (Wilson et al., 1990) , more widespread expression resulting in death.
A third viral protein, EBNA-LP, has an important auxiliary role in growth transformation by EBV. Although its biochemical function is unknown, the protein was recently reported to co-localize with a biochemically distinct fraction of the retinoblastoma gene protein to large granular structures within the nucleus, as also observed for the simian virus 40 (SV40) T antigen (Jiang 0001-1421 © 1993 SGM D. S. Huen and others et al., 1991 . Viruses with mutations in the EBNA-LP gene are greatly impaired in their ability to transform B lymphocytes (Hammerschmidt & Sugden, 1989; Mannick et al., 1991) . EBNA-LP is a polymorphic protein consisting of a varying number of amino-terminal repeats of a motif rich in basic residues, and a short unique carboxy-terminal domain with some similarity to a region of the adenovirus 5 E1A protein (Bodescot et al., 1984; Huen et al., 1988; Sample et al., 1986) . The repeat motifs in EBNA-LP are each encoded by a pair of exons within a series of 3.4 kb direct repeats in the viral genome. The EBNA-LP open reading frame (ORF) occurs within the leader region of mRNAs encoding each of the other EBNAs, derived by alternative processing of large primary transcripts from the C and W promoters. The initiation codon of EBNA-LP is assembled by only two of four alternative splices at the 5' end of this transcript (Rogers et al., 1990; Sample et al., 1986) .
As an approach to investigating the roles of the EBV latent gene products in cell transformation and tumorigenesis we attempted the expression of several of the proteins, including EBNA-LP, in transgenic mice. Initially we produced three lines of transgenic mice in which the EBNA-LP cDNA was coupled to the immunoglobulin heavy chain enhancer with an SV40 promoter, in an attempt to achieve B cell-specific expression; however mice in these lines did not express the transgene (D. S. Huen et al., unpublished results). We describe here several lines of transgenic mice expressing EBNA-LP from a metallothionein promoter, in a variety of tissues. There were no apparent oncogenic consequences of EBNA-LP expression. Unexpectedly however, after several months of apparent good health, transgenic mice in multiple independently derived lineages became ill and died prematurely of congestive (or dilated) heart failure. The highly predictable development of this condition in these transgenic mice suggests that they may be a valuable model for the pathophysiological changes occurring in human dilated cardiomyopathy.
Methods

Construction of MT-LP-hGH fusion gene.
Plasmid pUC-LP contains the EBNA-LP-encoding portion of the T65 cDNA cloned into the SmaI site of pUC18 (Sample et al., 1986 ; gift of Dr F. Wang, Boston, Mass., U.S.A.). A 1.8 kb BamHI-HindIII fragment from the human growth hormone (hGH) gene was inserted between the BamHI and HindIII sites within the polylinker downstream of the EBNA-LP ORF to form p(DH55)LP-hGH. A 1"7 kb EcoRI-BglII fragment containing the mouse metallothionein-I (MT) promoter and transcription initiation site was then inserted upstream of the LP-hGH fusion gene between the EcoRI and KpnI sites of the pUC18 polylinker to give p(DH61)MT-LP-hGH. The injected fragment was excised from the polylinker as a 4.5 kb EcoRI HindIII fragment (shown schematically in Fig. l b) and separated from vector sequences by agarose gel electrophoresis, electroelution and recovery using a QIAGEN tip-20 (Diagen).
Production of transgenic mice. Procedures were essentially as described (Hogan et al., 1986) . Briefly, the purified DNA fragment (MT-LP-hGH) was microinjected into fertilized mouse eggs derived from C57BL/6JxCBA/Ca F a hybrid parents. The manipulated embryos were cultured overnight and then re-implanted into pseudopregnant female mice. This resulted in the birth of 35 pups, of which 30 survived to weaning age. Transgenic progeny were identified by hybridizing dot blots of tail DNA with a probe spanning the LP-hGH portion of the construct (indicated in Fig. 1 b) . All procedures using animals were carried out with the authority of appropriate Home Office Project and Personal Licenses.
Transgene analysis of genomic DNA. Genomic DNA samples from the tail (5 ~tg) were digested with the appropriate restriction enzyme as recommended by the supplier in a total volume of 40 ~tl. Samples were then electrophoresed in a Tris-acetate-EDTA-buffered agarose gel and vacuum-transferred to Hybond-N+ nylon membranes (Amersham). Hybridization was performed as described by Sambrook et al. (1989) using a 32P-labelled random-primed probe prepared by using an ofigolabelling kit (Pharmacia).
Detection of EBNA-LP in transgenic mouse tissues. Tissue samples were homogenized in chilled RIPA buffer (20 mM-Tri~HC1 pH 7"5, 5mM-EDTA, 400mM-NaC1, 0.5% Triton X-100, 0"5% sodium deoxycholate, 0" 1% SDS) using an Ultra-Turrax homogenizer (Janhke & Kunkel). Contaminating serum immunoglobulins were removed by preclearing the samples with anti-mouse immunoglobulin-Sepharose beads. These were prepared by binding a goat anti-mouse immunoglobulin serum (Sigma) to CNBr-activated Sepharose 4B beads (Sigma) as indicated in the manufacturer's instructions. Protein concentrations were determined using the phenol-tannic acid method (MejbaumKatzenellenbogen & Dobryszycka, 1959) . Protein samples (100 ~tg) were separated on SDS~olyacrylamide gels and electrophoretically transferred onto nitrocellulose membranes (Gelman) essentially as described (Towbin et al., 1979) . Transferred protein was visualized using Ponceau S (Sigma) and the positions ofM r markers (Sigma) were noted. The filter was then blocked with BLOTTO, a 5 % suspension of non-fat dried milk in PBS supplemented with 0.1% Tween-20 (PBS-Tween) for 1 h. A mouse monoclonal antibody (MAb) specific for EBNA-LP (JF186, kind gift of Dr M. Rowe; Finke et al., 1987) , was then applied to the filter as a 10-fold dilution of hybridoma supernatant in BLOTTO and incubated at 4 °C overnight, then washed with three changes of PBS-Tween. The filter was then incubated with a 1000-fold dilution of rabbit anti-mouse IgG (Dakopatts) for 1 h and washed again with three changes of PBS-Tween. Finally, the filter was incubated with 20 pCi of radioiodinated Protein A (Amersham) in BLOTTO for 3 h, washed as before with PBS-Tween and exposed to X-ray film (Kodak X-Omat S).
Ventricular weights. Ventricular weights were measured using hearts fixed for 24 h in formal saline. The atria were removed, then the free right ventricular wall was excised along its margin with the interventricular septum. The left ventricle was then cut open longitudinally, both ventricles were washed free of blood and clots and patted dry with paper tissue. The free wall of the right ventricle, and the left ventricle with interventricular septum were then weighed (see Table 1 ).
Electrocardiography. Electrocardiograms (ECGs) were recorded from subcutaneous needle electrodes placed above the right shoulder and lower left ribcage of the dorsal surface of mice under Hypnodil (metomidate hydrochloride) anaesthesia. Signal amplification was achieved with Neurolog equipment (Digitimer) incorporating a 0-5 Hz to 300 Hz bandpass and 50 Hz notch filter. Data capture was achieved by the use of a pulse code modulator (Sony 501-ES) sampling at 44.1 kHz and recorded on a VHS video recorder. ECG profiles were obtained by playback of recorded material and examination on a digital oscilloscope equipped with hardcopy facilities (Gould 420).
Results
Production of EBNA-LP transgenic mice
To produce transgenic mice expressing EBNA-LP, mouse zygotes were injected with the M T -L P -h G H gene construct shown diagrammatically in Fig. 1 (b) , in which a c D N A fragment encoding EBNA-LP was placed downstream of the mouse MT promoter region. Sequences encompassing most of the h G H gene transcription unit and 3' sequences were included downstream of the EBNA-LP c D N A to provide splice and poly(A) signals. Three founder transgenic mice (designated 53-2, 53-18 and 53-26) were identified by dot blot analysis of tail DNA. On subsequent breeding, the variation among progeny in signal intensity on dot blots, and in the case of 53-2 a high proportion of transgenic progeny (16 out of 20), suggested that each of the founder mice had incorporated transgene copies in at least two segregating sites in the genome, and therefore, multiple sublines were established by further breeding of several offspring from each of the original transgenic founders. . The transgene loci in these two sublines are therefore considered to result from independent integration events. In contrast, the pattern obtained with subline 53-2C D N A is similar to that obtained with subline 53-2B. Although there are subtle differences such as the faint band of about 5.8 kb observed in 53-2B and not in 53-2C, the similarities suggest that these two sublines carry derivatives of the same transgene locus which has subsequently undergone additional minor rearrangements in at least one of the lineages. By similar reasoning, the transgene loci in sublines 53-18B and -C may be related whereas that in subline 53-18D probably results from an independent integration event. Two sublines were also established from transgenic founder 53-26; however, one of these, 53-26X, was lost at an early stage owing to the disease phenotype described below. The absence of this phenotype in the surviving subline, 53-26A, suggests that these two lineages must also have received distinct transgene loci. As listed in Table 1 , the number of copies of the M T -L P -h G H gene in the different sublines ranged from about 2 to 100.
Expression of EBNA-LP
Expression of EBNA-LP in tissues of transgenic mice from each of the surviving sublines was detected by probing Western blots with an anti-EBNA-LP M A b (Fig. 2) . The 66K band present in the negative control as well as the transgenics is attributed to mouse serum albumin in the samples, detected with the rabbit antimouse immunoglobulin second-step antibody. The EBNA-LP c D N A incorporated into the transgene construct contained five copies of the repeated exon pair, and encoded a 42K EBNA-LP. A band of this size was seen in several tissues from mice in each subline. The top panel in Fig. 2 shows expression in the heart, and it is apparent that in addition to the 42K band seen in each of these transgenic sublines, EBNA-LPs both larger and smaller than the main band are expressed at significant levels in several sublines. Different isolates of EBV contain a variable number of copies of the genomic 3.4 kb repeats including the repeated exons of EBNA-LP mRNA; even during infection of human B cells with a single EBV isolate, the EBNA-LP produced is heterogeneous in size. This is caused by splicing of a variable number of the repeated exons into the mRNA, as seen in the positive control sample from the LCL X50-7 in which the 42K EBNA-LP is a minor species. However as a cDNA was used in the transgene construct, such variable splicing cannot be the cause of EBNA-LP size heterogeneity in the transgenic mice. Southern blotting of genomic DNA using restriction enzyme sites that flank the repeats, resulting in smaller fragments and hence greater resolution than seen in the blot shown in Fig.  1 (a) , indicated that the size variation of EBNA-LP in the transgenic mice correlated with differences in the number of 198 bp exon pair repeats in the genomic transgene copies (data not shown). These may have arisen by unequal recombination and, as the patterns appear to be stably inherited, probably occurred during transgene integration. A wide variation of EBNA-LP size was also observed with both vaccinia virus and baculovirus recombinants incorporating the same cDNA, which suggests that the ENBA-LP repeats are strongly recombinogenic (M. Rowe, A. H. Davies & D. S. Huen, unpublished observations). The lower panels of Fig. 2 show only the 42K band of EBNA-LP detected in liver, kidney, lung and spleen. Each of these other tissues gave the same characteristic pattern of additional EBNA-LP bands as seen in the heart (top panel). The heart blot shown was overexposed in order to show the weaker EBNA-LP bands; in the 53-2B and -C sublines for example, similar levels of EBNA-LP were present in the heart and liver samples. The relative levels of expression in the different tissues varied between different lineages. For example, in subline 53-26A, expression in the heart was the lowest observed whereas expression in the liver was relatively high, exceeded only by that in subline 53-18D. Expression in the lung and spleen was detectable only in the 53-18 sublines, at levels appreciably lower than in kidney, liver or heart. Subline 53-26X was shown to express EBNA-LP strongly in liver and kidney; other tissues were not tested before the subline was lost. Immunohistochemical localization of EBNA-LP in sublines of 53-2 and 53-18 showed the protein to be localized to the nucleus of hepatocytes in liver sections and cardiomyocytes in the heart (data not shown).
Heart disease in EBNA-LP transgenic mice
After several months of apparent good health, transgenic mice in all sublines derived from transgenic founders 53-2 and 53-18, and one of the two 53-26 sublines, became ill, showing symptoms of respiratory distress. If not killed at the appearance of symptoms, such animals died typically within 1 to 3 days. Mice which had died or were killed when symptoms became apparent were found to have fluid in the lung alveoli (pulmonary oedema) and pleural cavity (hydrothorax). Abnormalities of the heart were also invariably observed, including distention of the left atrium by a prominent thrombus as shown in Fig.  3(b) . Microscopic examination of the atrial thrombi revealed large numbers of erythrocytes enmeshed between strands of fibrin, indicative of formation under conditions of circulatory stasis. The right atrium was also often enlarged to a lesser extent, without the . Lane 8, non-transgenic mouse. Lane 9, positive control sample that contains protein from 2 million X50-7 cells, which produce a predominant EBNA-LP larger than that encoded by the injected transgene; a 42K EBNA-LP equivalent to that expected in the mice is present as a minor species (as indicated). Values of M r markers (right) are shown on the left. The top panel shows heart samples; this autoradiograph was exposed for 1 week to show the fainter signals of some sublines and the variant EBNA-LPs. Liver and kidney samples gave similar patterns of variant EBNA-LPs; only the 42K regions of the blots are shown. These were exposed for 1 day to avoid overexposure. The blots of lung and spleen were also exposed for 1 week to show the low level expression of the 42K EBNA-LPs; variant EBNA-LPs were below the limit of detection.
presence of a thrombus. The ventricles appeared to be dilated with a larger cavity and thinner walls than control hearts, as shown in Fig. 3(b, d) . Equivalent sections of normal hearts are shown in (a) and (c). Transgenic mice examined prior to the development of respiratory distress did not show these abnormalities (data not shown).
To determine whether ventricular hypertrophy contributed to the pathology, hearts from normal nontransgenic mice, presymptomatic and symptomatic transgenic mice were dissected and the right and left ventricles were weighed. As shown in Table 2 , there was no significant difference in the mass of the ventricles in presymptomatic transgenic mice compared to nontransgenic controls. In symptomatic transgenic animals, a 40 to 80 % increase in the mass of the right ventricle was apparent, whereas there was no change in the left ventricular weight. Light microscopic examination of the myocardium did not reveal obvious fibrosis, lymphocytic infiltration, myocyte hypertrophy or other histological abnormality; however in electron micrographs, regions of myofibrillar disarray were apparent particularly in the left atrium of affected animals. Fig. 4(b) shows the typical ordered arrangement of myofibrils running in the plane of the section in atrial myocytes from a nontransgenic control mouse. In contrast, atrial myocytes from an affected transgenic mouse contain myofibrils running in several directions, both in the plane of the section and perpendicular to the section (Fig. 4a) . Similar changes, though less extreme, were observed also in some transgenic mouse ventricular myocytes, including some from presymptomatic mice.
The disease was limited to transgenic mice within susceptible sublines; non-transgenic littermates were unaffected. Fig. 5 shows typical cumulative mortality curves (for sublines 53-2C and 53-18D). No transgenic animals in subline 53-2C survived beyond 296 days, and the majority developed heart disease between 125 and 200 days of age (black area of chart). Some transgenic mice were killed for experimental purposes prior to the development of symptoms; these are shown in the crosshatched area. Although it is obvious that only surviving animals could be used, these were chosen essentially at random within the age range at which heart disease develops, and so it is unlikely that we inadvertently selected animals which would not have developed heart disease. We conclude that in this subline the incidence of heart disease is essentially 100%. Mice in subline 53-18D developed heart disease over a greater range of ages, i.e. from 227 to 556 days (Fig. 5b) , although it again appears that all transgenic mice in this subline would ultimately develop the same pathology.
A summary of the mortality data for each of the sublines is shown in Table 1 . All transgenic mice in subline 53-26X died by 5 months of age, leading to the loss of this line at an early stage. Subline 53-26A is the only lineage in which heart disease was not observed among 139 transgenic animals, of which 30 were monitored for over 400 days. In subline 53-2A the mean age at which heart disease develops approaches the normal lifespan of laboratory mice. Fewer mice in this subline were monitored for the long period necessary, but we estimate that around 50 % of animals develop congestive heart failure before other causes of death intervene.
ECG findings
The pathological findings in symptomatic M T -L P -h G H transgenic mice described here indicated that heart dysfunction was a major feature of the disease. In order to investigate heart function non-invasively in live mice, ECGs were obtained from control non-transgenic mice, presymptomatic and symptomatic transgenic mice (see Fig. 6 ). Murine ECGs differ from the usual human ECG pattern in that the QRS complex (associated with ventricular depolarization) and the T wave (associated with ventricular repolarization) are not distinctly separated (Richards et al., 1953) . In addition to the T wave, which appeared within the QRS complex, two further peaks of uncertain origin were noted to the right of the QRS complex in our recordings (labelled U and V in Fig.   6 ). The non-transgenic controls and most transgenic mice without visible disease symptoms showed essentially identical ECGs (Fig. 6, top two traces) . In transgenic mice showing mild respiratory distress soon after the onset of symptoms, the size of the T wave was reduced, and the U wave increased in size (Fig. 6, third trace) . ECGs from a few animals not showing obvious symptoms also showed T wave reduction, suggesting that this might be an early indicator of the onset of disease. In more severely affected animals (bottom trace) the T wave Female* Control 18.7 ± 1.6 79.1 ± 6.9 6 Presymptomatic 17.9 ± 1.8 76.6 ± 3.5 9 Symptomatic 32.3 ± 6"4t 79.3 ± 13.3 5 * Data for male and female mice are shown separately because the hearts of males were significantly heavier than those of females. Transgenic mice were classified as presymptomatic (i.e. normal appearance) or symptomatic (showing signs of respiratory distress when killed); controls were non-transgenic littermates.
~ For both males and females, right ventricles were significantly heavier in symptomatic than either control or presymptomatic mice (significant at 95 % level using Scheffe's F-test).
was further reduced and in some cases was almost unrecognizable.
Atrial fibrillation was considered a possible reason for the consistent distension and thrombus formation within the left atrium, while ventricular fibrillation would contribute to a reduced pumping efficiency and dilatation of the ventricles. However the ECGs from transgenic mice at all stages of disease progression showed a normal rhythmicity indicating the absence of either atrial or ventricular fibrillation. Also, as is apparent from the alignment of ECGs in Fig. 6 (left panels), the time interval between atrial and ventricular depolarization (P to R) shows little change, indicating the absence of conduction blocks at the atrial-ventricular junction; similarly, despite the amplitude changes, the timing of the R, T, U and V waves appeared unchanged. No consistent changes in heart rate were noted, although some variability between animals was observed, possibly due to variation in the depth of anaesthesia.
D&cussion
We have established several transgenic mouse lineages carrying the MT-LP-hGH gene construct designed to express EBNA-LP from the mouse metallothionein promoter, in a broad variety of tissues. We demonstrated that EBNA-LP was expressed in each of these, at varying levels in liver, kidney, spleen, lung and heart. Although the MT promoter used in the construct is inducible by heavy metal ions such as zinc and cadmium, all the results described in this paper were due to the constitutive, non-induced activity of the promoter. Transgenic mice in the majority of these lineages reproducibly develop cardiopulmonary disease, within an age range characteristic of the particular lineage. The appearance of the same disease pathology in transgenic mice derived from each of three original transgenic founder animals indicates that the disease must be due to expression of the transgene rather than to a chance mutation of the host genome associated with transgene integration.
Downstream of the EBNA-LP coding sequence, the transgene construct also contained most of the transcription unit from the hGH gene, included to allow efficient nuclear processing of the RNA transcript; the resulting mRNA is therefore expected to contain an D. S. Huen and others The upper line indicates the number of transgenic mice which have been monitored to a particular age. The black area indicates the cumulative incidence of dilated heart failure, and includes both animals which were found to have died with congestive heart failure and those which were found with symptoms and humanely killed. The cross-hatched area represents animals which were killed for experimental purposes prior to the development of symptoms.
intact hGH ORF downstream of that encoding EBNA-LP. It appears unlikely that significant levels of hGH would be translated from this hybrid mRNA, and in accordance with this expectation the transgenic mice did not grow larger than their transgenic littermates, as observed with MT-hGH transgenic mice (Palmiter et al., 1983) . Furthermore, since MT-hGH transgenic mice did not develop the pathology we observed (Brem et al., 1989) , we conclude that a possible low level of hGH synthesis does not contribute to development of cardiopulmonary disease in MT-LP-hGH transgenic mice. The latter do not develop turnouts at a rate detectably greater than non-transgenic littermates, suggesting that EBNA-LP does not have an independent transforming ability. Nevertheless, deletion mutants of EBV lacking the EBNA-LP carboxy-terminal sequence were greatly impaired in their ability to transform B cells in vitro (Allan et al., 1992; Hammerschmidt & Sugden, 1989; Mannick et al., 1991) . These two observations may be reconciled only if EBNA-LP can facilitate growth transformation in cooperation with some other EBV gene product. The principle of oncogene cooperation to give a greater rate of cell transformation in vitro or tumorigenesis in transgenic mice than seen with either oncogene alone is firmly established (Choi et al., 1988; van Lohuizen et al., 1989; Hunter, 1991) . It will be of interest to test the ability of other EBV genes to cooperate with EBNA-LP and induce tumours, using the MT-LP-hGH transgenic mice that live longer. However it should be noted that expression of EBNA-LP was detected in the spleen only in the 53-18 sublines, and here the level was very low. The possibility that higher levels of EBNA-LP may elicit an observable phenotype in lymphocytes cannot therefore be excluded. The pathological features of the disease produced in the MT-LP-hGH transgenic mice are indicative of congestive heart failure. Heart failure in man can occur secondary to hypertension (high blood pressure); however the increased resistance presented to the heart in this condition induces growth of cardiomyocytes in the left ventricle resulting in left ventricular hypertrophy, which was not present at any stage of the disease in our transgenic mice. Furthermore hypertensive transgenic animals have been produced, yet these were not reported to develop the cardiopulmonary pathology described here (Kimura et al., 1992; Mullins et al., 1990) . The consistent dilatation of the left ventricle in affected transgenic mice without accompanying hypertrophy suggests an underlying ventricular insufficiency. A reduction in left ventricular output would impede pulmonary drainage, increasing the pressure within the pulmonary circulation. This could cause extravascular fluid retention in the lungs and pleural cavity, giving rise to oedema and hydrothorax. The hypertrophy observed in the right ventricle of symptomatic transgenic mice is a normal response to pulmonary hypertension, but may further aggravate the problems. Increased pressure in the pulmonary circulation may contribute to distension of the left atrium, and the contraction of atrial myocytes may also be compromised, as suggested by the observation of myofibrillar disarray. The combined effects presumably cause thrombus formation, either because of abnormal turbulence or, more probably as suggested by the entrapment of erythrocytes within the clot, because of stasis of the blood in the atrial appendage. Once formed, the thrombus would further impair cardiac function and pulmonary drainage, leading to escalation of the effects and the appearance of visible symptoms.
The molecular mechanism by which EBNA-LP causes heart failure in the transgenic mice is not clear; however the observation of a reduced T wave amplitude in ECGs of affected animals and a proportion of the presymptomatic transgenic mice suggests that a defect ofventricular repolarization develops in the transgenic mice and may contribute to the end-stage disease. It appears most likely that the cardiomyocytes themselves are the relevant target cells for EBNA-LP expression and, with one anomaly (subline 53-18B), there does appear to be a correlation between the level of EBNA-LP expressed in the heart and the severity of the disease, as judged by the age of onset (see Table 1 ). However it is possible that the effect could result from expression of EBNA-LP in a particular region of the myocardium or even in a remote tissue with an effect on heart function. The role of EBNA-LP in the viral life cycle also remains unknown, although the short region of identity with adenovirus 5 E1A protein and co-localization with the retinoblastoma susceptibility gene product to granules within the nucleus suggest that it may share cellular targets in common with the oncogenes of other DNA tumour viruses, perhaps affecting the transcriptional regulation of specific genes (Huen et al., 1988; Jiang et al., 1991) . A plausible hypothesis to explain a role in the heart disease pathogenesis is that EBNA-LP might affect the expression of genes involved in the normal function of the heart, such as those encoding ion channels. Heart disease has been described previously in only a few lines of transgenic mice, and in none of these does the pathology appear identical to that described here. Expression of the SV40 T antigen using the promoter of the atrial natriuretic factor gene in transgenic mice caused hyperplasia and a several hundredfold increase in size of the right atrium (Field, 1988) . The ECGs of such mice were dominated by arrhythmias apparently due to the development of multifocal pacemakers in the grossly enlarged atrium. Cardiac expression of the c-myc gene resulted in modest enlargement of the heart as a result of myocyte hyperplasia, although in other respects the myocardium appeared normal as judged by the absence of fibrosis and expression of the appropriate actin isoform (Jackson et al., 1990) ; these mice were not reported to become ill with heart disease. Enlargement of the heart was also a feature of v-fps transgenics in which a form of congestive heart disease was observed; this was accompanied by degeneration of cardiomyocytes and marked fibrosis of the left ventricular wall, features absent in the MT-LP-hGH transgenic mice (Yee et al., 1989 ). The transgenic model most similar to that described here is a single line of mice expressing polyomavirus large T antigen (PVLT), also from the MT promoter, reported while this work was in progress (Chalifour et al., 1990) . These MT-PVLT mice developed congestive heart failure and were also found to develop a left atrial thrombus. However the entire heart was enlarged three-to 4.5-fold in the MT-PVLT transgenic mice, and both vacuolar degeneration of myocytes and interstitial fibrosis were apparent in the heart wall. This contrasts with our MT-LP-hGH transgenic mice in which there was no apparent underlying hypertrophy or fibrosis. Nevertheless the causation of congestive heart disease by both PVLT and EBNA-LP is consistent with the hypothesis that these proteins may share cellular targets. The differences in phenotype may relate to the known ability of papovavirus large T antigens to interact with a wide range of cellular growth-regulatory proteins in contrast to the more limited selection expected for the smaller, less complex EBNA-LP.
The disease produced by expression of EBNA-LP in transgenic mice has some similarity to human congestive heart failure or dilated cardiomyopathy (DCM), in which dilatation of the ventricles occurs without a proportionate increase in myocardial mass. In man DCM has an estimated incidence of at least five to 10 per 100000 per year (Torp, 1980) and is associated with a high mortality; end-stage disease can only be effectively treated by heart transplantation (Brandenburg, 1985) . Several possible causes have been proposed for DCM in man, including alcohol abuse, viral infection and autoimmunity. Each of these may play a leading role in some cases; however there remains a high proportion of cases for which the cause is unknown (Olsen, 1985; Wynne & Braunwald, 1988) . The results presented here suggest that the EBNA-LP of EBV can cause heart failure in mice, indicating that individual viral proteins can potentially precipitate heart failure, even without the associated events of viral infection. Despite the widespread presence of EBV in the human population, it appears unlikely that EBNA-LP plays a role in the aetiology of human DCM as EBV is not known to infect heart tissue. Although the primary insult may differ, many features of disease progression may be similar in MT-LP-hGH transgenic mice and human DCM patients, and EBNA-LP may even mimic the effect of an initiating infection by another virus. The highly predictable development of dilated heart failure in transgenic mice expressing EBNA-LP as described here should facilitate investigation of the pathophysiological changes associated with ventricular dilatation, and may be valuable in the development of preventative or therapeutic approaches to human DCM.
